USA - NASDAQ:GH - US40131M1099 - Common Stock
The current stock price of GH is 91.355 USD. In the past month the price increased by 50.36%. In the past year, price increased by 301.78%.
|  Symbol  |  Company Name  |  TA  |  FA  |  PE  |  Market Cap  | 
|---|---|---|---|---|---|
| CVS | CVS HEALTH CORP | 11.15 | 96.86B | ||
| CI | THE CIGNA GROUP | 8.54 | 64.80B | ||
| LH | LABCORP HOLDINGS INC | 16.1 | 21.17B | ||
| BTSGU | BRIGHTSPRING HEALTH SERV - BTSG 6 3/4 02/01/27 | 203.25 | 19.80B | ||
| DGX | QUEST DIAGNOSTICS INC | 18.07 | 19.72B | ||
| FMS | FRESENIUS MEDICAL CARE-ADR | 13.3 | 15.69B | ||
| HIMS | HIMS & HERS HEALTH INC | 56.74 | 10.26B | ||
| DVA | DAVITA INC | 12.28 | 8.51B | ||
| CHE | CHEMED CORP | 19.82 | 6.35B | ||
| RDNT | RADNET INC | 211.42 | 5.85B | ||
| BTSG | BRIGHTSPRING HEALTH SERVICES | 59 | 5.75B | ||
| OPCH | OPTION CARE HEALTH INC | 17.05 | 4.12B | 
 Guardant Health, Inc. is a precision oncology company, which engages in the provision of treatment of cancer through the use of proprietary blood-based tests, vast data sets, and advanced analytics. The company is headquartered in Palo Alto, California and currently employs 1,999 full-time employees. The company went IPO on 2018-10-04. The company provides critical insights into what drives disease through its advanced blood and tissue tests, real-world data, and artificial intelligence (AI) analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the treatment for patients with advanced cancer. For patients with advanced-stage cancer, it has developed Guardant360 laboratory developed test (LDT), and Guardant360 CDx test, a comprehensive liquid biopsy test to provide tumor mutation profiling with solid tumors and to be used as a companion diagnostic in connection with non-small cell lung cancer (NSCLC), and breast cancer. The company offers other tests, including Guardant360 Tissue test, Guardant Reveal blood test, Guardant360 Response blood test and others.
GUARDANT HEALTH INC
3100 Hanover Street
Palo Alto CALIFORNIA 94063 US
CEO: Helmy Eltoukhy
Employees: 1999
Phone: 18556988887
Guardant Health, Inc. is a precision oncology company, which engages in the provision of treatment of cancer through the use of proprietary blood-based tests, vast data sets, and advanced analytics. The company is headquartered in Palo Alto, California and currently employs 1,999 full-time employees. The company went IPO on 2018-10-04. The company provides critical insights into what drives disease through its advanced blood and tissue tests, real-world data, and artificial intelligence (AI) analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the treatment for patients with advanced cancer. For patients with advanced-stage cancer, it has developed Guardant360 laboratory developed test (LDT), and Guardant360 CDx test, a comprehensive liquid biopsy test to provide tumor mutation profiling with solid tumors and to be used as a companion diagnostic in connection with non-small cell lung cancer (NSCLC), and breast cancer. The company offers other tests, including Guardant360 Tissue test, Guardant Reveal blood test, Guardant360 Response blood test and others.
The current stock price of GH is 91.355 USD. The price decreased by -1.14% in the last trading session.
GH does not pay a dividend.
GH has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
GUARDANT HEALTH INC (GH) operates in the Health Care sector and the Health Care Providers & Services industry.
GUARDANT HEALTH INC (GH) has a market capitalization of 11.39B USD. This makes GH a Large Cap stock.
GUARDANT HEALTH INC (GH) will report earnings on 2026-02-18, after the market close.
ChartMill assigns a technical rating of 10 / 10 to GH. When comparing the yearly performance of all stocks, GH is one of the better performing stocks in the market, outperforming 98.42% of all stocks.
ChartMill assigns a fundamental rating of 3 / 10 to GH. Both the profitability and financial health of GH have multiple concerns.
Over the last trailing twelve months GH reported a non-GAAP Earnings per Share(EPS) of -2.91. The EPS increased by 17.09% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -31.07% | ||
| ROE | N/A | ||
| Debt/Equity | N/A | 
34 analysts have analysed GH and the average price target is 69.28 USD. This implies a price decrease of -24.17% is expected in the next year compared to the current price of 91.355.
For the next year, analysts expect an EPS growth of 10.91% and a revenue growth 26.22% for GH